查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1820260

2025 年至 2033 年疫苗佐剂市场规模、份额、趋势及预测（依产品类型、给药途径、疾病、应用及地区）

Vaccine Adjuvants Market Size, Share, Trends and Forecast by Product Type, Route of Administration, Diseases, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球疫苗佐剂市场规模达11.07亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到28.517亿美元，2025-2033年期间的复合年增长率（CAGR）为10.53%。全球疫苗佐剂市场正在快速增长，原因包括传染病发病率的上升、免疫学和疫苗技术的重大里程碑、人们对罕见疾病的认识不断提高、未开发人群对大流行性疫苗接种工作的兴趣日益浓厚、政府支出不断增加以及老年人对有效疫苗接种的需求。

疫苗佐剂市场趋势：

疫苗和免疫学技术的进步

免疫学在疫苗佐剂开发方面取得了重大进展，新型佐剂比以前认为的更有效、更安全。技术进步使得设计能够选择性增强对抗原的免疫反应的佐剂成为可能，这显着提高了疫苗对抗世界各地多种病原体的能力。最近，在 2024 年 2 月，艾伯维和 Tentarix Biotherapeutics 宣布建立多年战略合作伙伴关係，开发肿瘤学和免疫学领域的生物候选药物。该协议价值超过 6400 万美元。候选药物的开发将结合艾伯维在肿瘤学和免疫学方面的能力与 Tentarix 专有的 Tentacles 平台，以发现和开发针对每个医学分支中一个靶点的条件活性、多特异性生物製剂。这将激活可以调节疾病途径的免疫细胞，同时减少通常与非特异性治疗相关的安全问题。

提高对罕见疾病的认识与理解

人们对罕见疾病的认识不断提高，这加速了疫苗研发中的独特挑战。这种新认识激起了人们对可根据不同利害关係人的特定需求量身定制的疫苗佐剂的兴趣。至于欧盟，他们将罕见疾病定义为欧洲人口中每 10 万人中影响不到 50 人。然而，美国《门诊孤儿药法案》将罕见疾病定义为美国每 10 万人中影响不到 20 万人。其他定义包括刚果每 10 万人中最低为 5 人，而印度每 10 万人中最高为 76 人。平均而言，全球每 10 万人中就有 40 人患有罕见疾病。最近，根据 3,585 名罕见疾病患者的数据，罕见疾病的盛行率为世界人口的 3.5% 至 5.9%，相当于 2.63 亿至 4.46 亿人。

全球推动疫苗接种，因应流行病威胁

以COVID-19为代表的流行病威胁的对抗引发了一场前所未有的全球疫苗接种运动，使疫苗佐剂市场成为公共卫生重点关注的焦点。此外，疫苗佐剂的主要用途是增强免疫反应、提高疫苗稳定性、提高疫苗效力和减少疫苗剂量，这反过来又推动了市场的成长。 「根据ABC新闻报道，每週新增15,141例COVID-19住院病例。根据美国疾病控制与预防中心（CDC）的信息，这与2024年4月初的住院人数大致相同。但这一数字低于2022年1月22日当週（Omicron浪潮期间）每週150,650例美国住院病例的峰值报告美国住院病例。

疫苗佐剂市场区隔：

按产品类型细分：

  • 佐剂乳剂
  • 病原体成分
  • 颗粒佐剂
  • 组合佐剂
  • 其他的

佐剂乳液占据大部分市场份额

佐剂乳剂细分市场的发展源自于人们对高效、长效疫苗日益增长的需求。这种需求源自于乳剂佐剂能够激发强烈而广泛的免疫反应，使其成为流感和新冠肺炎等复杂疾病疫苗的理想选择。乳剂佐剂的多功能性以及与多种抗原的兼容性进一步提升了其吸引力。此外，奈米技术的进步改进了这些佐剂的递送机制，在保持安全性的同时提高了其有效性。持续进行的旨在优化乳剂配方的研发工作对于满足日益增长的疫苗佐剂市场需求至关重要，凸显了其在未来疫苗开发策略中的关键作用。

依给药途径分类：

  • 口服
  • 肌肉注射
  • 鼻内
  • 皮下
  • 皮内
  • 其他的

肌肉注射是领先的细分市场

肌肉注射细分市场的成长动力源于对需要深层组织渗透才能达到最佳疗效的疫苗（例如流感疫苗、破伤风疫苗和新冠肺炎疫苗）日益增长的需求。这种方法之所以受到青睐，是因为它能够将大量疫苗直接输送到血液供应丰富的肌肉中，促进更强、更快速的免疫反应。此外，与其他方法相比，肌肉注射途径因其给药相对简便、不适感最小、不良反应风险较低而受到青睐，使其成为全球疫苗接种计画中广泛接受的做法。疫苗吸收率的一致性以及支持其有效性的大量历史资料进一步增强了其应用，突显了该细分市场的成长。

依疾病分类：

  • 癌症
  • 传染病
  • 其他的

传染病占大部分市场份额

传染病细分市场的成长动力源于全球流行病和新兴传染病威胁的日益加剧，凸显了对有效疫苗的迫切需求。国际旅行、都市化和气候变迁等因素加剧了传染病的传播，因此需要快速开发和部署含有强效佐剂的疫苗。各国政府和国际上为对抗传染病而采取的倡议，以及在研发方面的大量投入，进一步推动了该细分市场的成长。此外，公众意识的提高和医疗基础设施的改善在支持疫苗接种计划方面发挥着至关重要的作用，从而增加了对用于有效对抗这些疾病的创新疫苗佐剂的需求。

按应用分类：

  • 研究
  • 商业的

研究代表了领先的细分市场

疫苗佐剂市场的研究领域受到日益增长的疫苗需求的推动，这些需求旨在针对更广泛的病原体（包括新兴和再发传染病）。这种需求与对免疫系统复杂性的日益加深的理解相结合，促使科学家探索能够引发更强、更持久免疫反应的新型佐剂配方。此外，个人化医疗和针对个人基因组成的疫苗的需求也推动了创新佐剂的探索。生物技术和奈米技术的进步进一步推动了这一领域的发展，使得能够精确设计下一代佐剂以增强疫苗有效性并最大程度地减少副作用。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据最大的疫苗佐剂市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是疫苗佐剂最大的区域市场。

北美疫苗佐剂预计将占据市场主导地位，因为该地区在疫苗研发方面投入了大量资金，旨在应对各种传染病以及公共和私营部门日益增长的健康问题。该地区拥有疫苗快速审批流程的优势，鼓励製药公司扩大并增加对佐剂技术的投资。此外，北美拥有许多顶尖研究中心的优势，并与生物技术产业保持着频繁的合作。因此，这里是医疗技术和创新的领域。此外，为了提高疫苗的有效性，佐剂的使用也更加重视提高疫苗的有效性和安全性，推动了北美市场的扩张。

（请注意，这只是关键参与者的部分名单，完整名单将在报告中提供。）

  • 疫苗佐剂市场的主要参与者正积极参与研发活动，以推出创新且更有效的佐剂配方。这些努力旨在增强疫苗引发的免疫反应，确保对各种传染病提供更广泛、更持久的保护，并开发针对癌症等慢性疾病的治疗性疫苗。例如，2022年2月，Novavax Inc.宣布其新冠候选疫苗NVX-CoV2373与其专有佐剂Matrix-M联合使用的III期临床试验取得了积极的中期结果。结果显示，NVX-CoV2373对新冠具有强大的疗效，整体有效率超过90%。合作与伙伴关係是一种常见的策略，它整合学术机构、研究组织和生技公司的专业知识，以加速下一代佐剂的开发。此外，这些公司正在投资先进技术，探索新型佐剂物质，包括合成分子和天然化合物，以提高疫苗的有效性和安全性。在企业应对复杂市场环境、将创新产品推向市场的过程中，合规性和快速审批流程也至关重要。透过这些倡议，关键参与者正在为全球疫苗佐剂市场的蓬勃发展和发展做出重大贡献。

本报告回答的关键问题

  • 2024年全球疫苗佐剂市场规模是多少
  • 2025-2033年全球疫苗佐剂市场的预期成长率是多少
  • 推动全球疫苗佐剂市场的关键因素有哪些
  • COVID-19 对全球疫苗佐剂市场有何影响
  • 根据产品类型，全球疫苗佐剂市场如何划分
  • 根据给药途径，全球疫苗佐剂市场如何划分
  • 全球疫苗佐剂市场依疾病类型划分如何？
  • 根据应用，全球疫苗佐剂市场如何划分？
  • 全球疫苗佐剂市场重点区域有哪些
  • 10. 全球疫苗佐剂市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2024年全球疫苗佐剂市场规模？ 2025-2033年全球疫苗佐剂市场的预期成长率是多少？
  • 推动全球疫苗佐剂市场发展的关键因素有哪些？
  • COVID-19 对全球疫苗佐剂市场有何影响？
  • 根据产品类型，全球疫苗佐剂市场是如何分布的？
  • 根据给药途径，全球疫苗佐剂市场如何分布？
  • 全球疫苗佐剂市场依疾病分类是怎样的？
  • 根据应用，全球疫苗佐剂市场是如何分布的？
  • 全球疫苗佐剂市场的主要地区有哪些？
  • 全球疫苗佐剂市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球疫苗佐剂市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品类型

  • 佐剂乳剂
  • 病原体成分
  • 颗粒佐剂
  • 组合佐剂
  • 其他的

第七章：市场区隔：依行政途径

  • 口服
  • 肌肉注射
  • 鼻内
  • 皮下
  • 皮内
  • 其他的

第 8 章：市场区隔：依疾病

  • 癌症
  • 传染病
  • 其他的

第九章：市场区隔：依应用

  • 研究
  • 商业的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adjuvatis
    • Agenus Inc.
    • Croda International Plc
    • CSL Limited
    • Dynavax Technologies
    • InvivoGen
    • Novavax Inc.
    • OZ Biosciences
    • Phibro Animal Health Corporation
    • SEPPIC
    • SPI Pharma
Product Code: SR112025A4385

The global vaccine adjuvants market size reached USD 1,107.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,851.7 Million by 2033, exhibiting a growth rate (CAGR) of 10.53% during 2025-2033. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie , and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

Breakup by Product Type:

  • Adjuvant Emulsions
  • Pathogen Components
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

Adjuvant Emulsions accounts for the majority of the market share

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

  • Oral
  • Intramuscular
  • Intranasal
  • Subcutaneous
  • Intradermal
  • Others

Intramuscular represents the leading market segment

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

  • Cancer
  • Infectious Diseases
  • Others

Infectious diseases accounts for the majority of the market share

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

  • Research
  • Commercial

Research represents the leading market segment

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Key Questions Answered in This Report

  • 1.What was the size of the global vaccine adjuvants market in 2024?
  • 2.What is the expected growth rate of the global vaccine adjuvants market during 2025-2033?
  • 3.What are the key factors driving the global vaccine adjuvants market?
  • 4.What has been the impact of COVID-19 on the global vaccine adjuvants market?
  • 5.What is the breakup of the global vaccine adjuvants market based on the product type?
  • 6.What is the breakup of the global vaccine adjuvants market based on route of administration?
  • 7.What is the breakup of the global vaccine adjuvants market based on the diseases?
  • 8.What is the breakup of the global vaccine adjuvants market based on the application?
  • 9.What are the key regions in the global vaccine adjuvants market?
  • 10.Who are the key players/companies in the global vaccine adjuvants market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Adjuvant Emulsions
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pathogen Components
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Particulate Adjuvants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Adjuvants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intramuscular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intranasal
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Subcutaneous
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intradermal
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Diseases

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Research
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Commercial
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Adjuvatis
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agenus Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Croda International Plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Dynavax Technologies
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 InvivoGen
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novavax Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 OZ Biosciences
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Phibro Animal Health Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 SEPPIC
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 SPI Pharma
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Vaccine Adjuvants Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Vaccine Adjuvants Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Vaccine Adjuvants Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Vaccine Adjuvants Market: Breakup by Diseases (in %), 2024
  • Figure 7: Global: Vaccine Adjuvants Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Vaccine Adjuvants Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Vaccine Adjuvants (Pathogen Components) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Vaccine Adjuvants (Pathogen Components) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Vaccine Adjuvants (Particulate Adjuvants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Vaccine Adjuvants (Particulate Adjuvants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Vaccine Adjuvants (Combination Adjuvants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Vaccine Adjuvants (Combination Adjuvants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Vaccine Adjuvants (Other Product Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Vaccine Adjuvants (Other Product Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Vaccine Adjuvants (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Vaccine Adjuvants (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Vaccine Adjuvants (Intramuscular) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Vaccine Adjuvants (Intramuscular) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Vaccine Adjuvants (Intranasal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Vaccine Adjuvants (Intranasal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Vaccine Adjuvants (Subcutaneous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Vaccine Adjuvants (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Vaccine Adjuvants (Intradermal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Vaccine Adjuvants (Intradermal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Vaccine Adjuvants (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Vaccine Adjuvants (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Vaccine Adjuvants (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Vaccine Adjuvants (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Vaccine Adjuvants (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Vaccine Adjuvants (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Vaccine Adjuvants (Other Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Vaccine Adjuvants (Other Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Vaccine Adjuvants (Research) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Vaccine Adjuvants (Research) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Vaccine Adjuvants (Commercial) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Vaccine Adjuvants (Commercial) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia-Pacific: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia-Pacific: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Vaccine Adjuvants Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Vaccine Adjuvants Industry: SWOT Analysis
  • Figure 91: Global: Vaccine Adjuvants Industry: Value Chain Analysis
  • Figure 92: Global: Vaccine Adjuvants Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Adjuvants Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Adjuvants Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Adjuvants Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Adjuvants Market Forecast: Breakup by Diseases (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Adjuvants Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Adjuvants Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Vaccine Adjuvants Market: Competitive Structure
  • Table 8: Global: Vaccine Adjuvants Market: Key Players